PURPOSE: The aim of this prospective cohort study was to examine uptake and psychological, behavioral, and cognitive outcomes of genetic testing for melanoma risk among individuals with a known family-specific CDKN2A mutation. METHODS: A total of 119 individuals were ascertained via a genetic epidemiological study and completed a series of mailed, self-administered questionnaires at multiple time points, including notification of genetic test availability, and 2 weeks and 12 months after receipt of genetic test results (for "test participants"), or 12 months after notification (for "decliners"). RESULTS: Since January 2005, 21% of participants (n = 25) have undergone genetic testing, with 75% of those who have received results identified as mutation carriers (n = 15). Factors associated with uptake of genetic counseling included perceived susceptibility to melanoma (odds ratio = 3.60, P = 0.0008), and fatalistic beliefs about melanoma (odds ratio = 0.57, P = 0.005). Compared with baseline, carriers reported significantly reduced anxiety scores at 2 weeks, and reduced depression scores at 2 weeks and 12 months, after receipt of genetic test results. Carriers also reported a significantly greater frequency of clinical skin examination at 12-month follow-up compared with decliners (chi2 = 5.70, P = 0.02). No hypothesis testing was carried out for noncarriers because of their limited number. CONCLUSION: These data provide preliminary evidence for healthy psychological, behavioral, and cognitive adjustment after participation in genetic testing for melanoma risk.
PURPOSE: The aim of this prospective cohort study was to examine uptake and psychological, behavioral, and cognitive outcomes of genetic testing for melanoma risk among individuals with a known family-specific CDKN2A mutation. METHODS: A total of 119 individuals were ascertained via a genetic epidemiological study and completed a series of mailed, self-administered questionnaires at multiple time points, including notification of genetic test availability, and 2 weeks and 12 months after receipt of genetic test results (for "test participants"), or 12 months after notification (for "decliners"). RESULTS: Since January 2005, 21% of participants (n = 25) have undergone genetic testing, with 75% of those who have received results identified as mutation carriers (n = 15). Factors associated with uptake of genetic counseling included perceived susceptibility to melanoma (odds ratio = 3.60, P = 0.0008), and fatalistic beliefs about melanoma (odds ratio = 0.57, P = 0.005). Compared with baseline, carriers reported significantly reduced anxiety scores at 2 weeks, and reduced depression scores at 2 weeks and 12 months, after receipt of genetic test results. Carriers also reported a significantly greater frequency of clinical skin examination at 12-month follow-up compared with decliners (chi2 = 5.70, P = 0.02). No hypothesis testing was carried out for noncarriers because of their limited number. CONCLUSION: These data provide preliminary evidence for healthy psychological, behavioral, and cognitive adjustment after participation in genetic testing for melanoma risk.
Authors: Jennifer M Taber; William M P Klein; Rebecca A Ferrer; Katie L Lewis; Leslie G Biesecker; Barbara B Biesecker Journal: Health Psychol Date: 2014-10-13 Impact factor: 4.267
Authors: Kate A McBride; Nina Hallowell; Martin H N Tattersall; Judy Kirk; Mandy L Ballinger; David M Thomas; Gillian Mitchell; Mary-Anne Young Journal: J Community Genet Date: 2015-05-26
Authors: Yelena P Wu; Lisa G Aspinwall; Elizabeth Nagelhout; Wendy Kohlmann; Kimberly A Kaphingst; Sheila Homburger; Ryan D Perkins; Douglas Grossman; Garrett Harding; Pamela Cassidy; Sancy A Leachman Journal: J Cancer Educ Date: 2018-08 Impact factor: 2.037
Authors: Erin Turbitt; Megan C Roberts; Jennifer M Taber; Erika A Waters; Timothy S McNeel; Barbara B Biesecker; William M P Klein Journal: Prev Med Date: 2019-02-25 Impact factor: 4.018
Authors: Lisa G Aspinwall; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman Journal: J Genet Couns Date: 2013-12-10 Impact factor: 2.537
Authors: Yelena P Wu; Lisa G Aspinwall; Bridgid M Conn; Tammy Stump; Bridget Grahmann; Sancy A Leachman Journal: Prev Med Date: 2016-04-16 Impact factor: 4.018
Authors: Amanda M Willis; Sian K Smith; Bettina Meiser; Mandy L Ballinger; David M Thomas; Martin Tattersall; Mary-Anne Young Journal: J Genet Couns Date: 2018-02-17 Impact factor: 2.537